Allergic rhinitis is a symptomatic disorder of the nose secondary to IgE-mediated inflammation of the nasal membranes induced after exposure to allergens.
Major symptoms include nasal itching, watery rhinorrhea, nasal obstruction/congestion, sneezing and postnasal drainage.
Other symptoms include headache, conjunctival symptoms, eye pruritus, impaired smell and morning cough.
Symptoms can reverse spontaneous w/ or w/o treatment.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
The fixed-dose combination of montelukast plus levocetirizine produces greater improvements in allergic rhinitis symptoms as compared with montelukast alone in patients with concurrent mild-to-moderate asthma, according to the results of a phase III trial. Moreover, the combination is well tolerated with an acceptable safety profile.
Transdermal administration of emedastine difumarate provides effective control of symptoms of seasonal allergic rhinitis, with the effects sustained throughout the day and raising no safety signals of clinical concern, according to the results of a phase III trial.
The presence of eczema or atopic dermatitis with concurrent allergic sensitization at 1 year of age was associated with an increased risk of developing asthma and food allergy in later childhood at 3 years old, according to the CHILD* study.
There are various ear, nose, and throat (ENT) conditions which present to the GP’s clinic. Dr Jason Hwang, an ENT Consultant from the Department of Otolaryngology at Gleneagles Hospital in Singapore, speaks on how the majority of the conditions can be effectively managed at the primary care level seeing that these can be treated medically without the need for surgical intervention.
Prolonged use of bilastine 20 mg one daily is safe and effective in the treatment of Japanese patients with seasonal (SAR) or perennial allergic rhinitis (PAR), as stated in an open-label, single-arm, phase III study.
Bilastine effectively reduces total nasal symptom scores (TNSS) in Japanese patients with perennial allergic rhinitis (PAR), a multicentre, randomised, double-blind, placebo-controlled, parallel group phase III study has shown.
A recent study has enumerated the following features that characterize patients treated in the emergency department (ED) for acute exacerbation of chronic obstructive pulmonary disease (AECOPD): they commonly arrive by ambulance, have a high admission rate and have significant in-hospital mortality.
A nationwide study has shown complex use patterns of long-acting beta2‐agonists (LABAs), long‐acting muscarinic antagonists (LAMAs) and inhaled corticosteroids (ICSs) in patients with chronic obstructive pulmonary disease (COPD). Often, such patterns do not comply with treatment guidelines.
Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).